AbstractRubia tibetica Hook. f is a traditional Tibetan medicinal plant, with its roots serving as the primary medicinal part. Two new compounds, Rubiaxylm C and E (1 and 3), and one new natural compound, Rubiaxylm D (2) were isolated from R. tibetica, along with five known compounds (4–8). The structures of the previously undescribed compounds were elucidated by HR‐ESIMS, 1D/2D NMR spectroscopic data and electronic circular dichroism calculations. Compound 1 is a rare anthrone substituted with a carbonyl group at position 1. Furthermore, all isolated compounds were tested for their cytotoxicity against HepG2 cell lines.

01 Jan 2025·Food Chemistry

Different extraction methods shape the phenolic signature and biological activity of Morinda lucida extracts: A novel source of bioactive compounds preparing functional applications

Article

Author: Del Vecchio, Gianmarco ; Zengin, Gokhan ; Terzic, Milena ; Bene, Kouadio ; Lucini, Luigi ; Zhang, Leilei ; Mahomoodally, Mohamad Fawzi ; Sinan, Kouadio Ibrahime

The extraction of bioactive compounds is based on the application of various extraction techniques. Therefore, the stem and root bark of the plant species Morinda lucida L. were used in this research, while the extraction procedure was performed using three extraction techniques: HAE (homogenizer extraction), UAE (ultrasound extraction) as modern, and MAC (maceration) as conventional extraction technique. The presence of different classes of secondary metabolites was determined using the UHPLC method, while the content of total phenols and flavonoids was determined spectrophotometrically. The biological potential was investigated by in vitro antioxidant and enzyme assays. Different extraction technologies showed significant differences in only two classes of phenols, namely lignans and phenolic acids, which were significantly higher in HAE than in UAE and MAC. These findings highlight the significant effect of stem and bark extracts of M. lucida, opening the way for innovative industrial exploitation of these matrices.

02 Dec 2024·American Journal of Audiology

Benefit–Cost Analyses of Hearing Aids, Over-the-Counter Hearing Devices, and Hearing Care Services

Article

Author: Huntington-Klein, Nick ; Jilla, Anna Marie ; Baldwin, Jonathan D. ; Johnson, Carole E.

Purpose:Limited accessibility to hearing health care threatens healthy aging in place for older adults with hearing loss. A willingness-to-pay (WTP) approach was used to determine benefits and value of prescription advanced digital technology (ADT) hearing aids, over-the-counter (OTC) hearing devices, and rehabilitative services using benefit–cost analyses.Method: This study was a cross-sectional survey with chart review of hearing aid users at two independent audiology practices. Seventy hearing aid users (response rate: 15.6%) provided their WTP for ADT prescription hearing aids, OTC hearing devices, and hearing rehabilitative services. Benefit–cost ratios and net social benefit were calculated using deterministic and exploratory approaches. Point estimates for benefit–cost ratios and net social benefit were derived using bootstrap sampling with replacement ( N = 5,000). Results: Median WTP for ADT prescription hearing aids and rehabilitative services were $2,000 and $250, respectively. WTP was lowest for OTC devices ( Mdn = $0; maximum = $500). Benefit–cost ratios and net social benefit for ADT prescription hearing aids, OTC devices, and hearing rehabilitative services favored these interventions when out-of-pocket costs remained low. Benefit–cost analyses also produced results favoring prescription ADT hearing aid intervention with costs as high as $1,530 per device. Conclusions:WTP results indicated that all interventions under study have a measurable consumer-perceived benefit. Results of benefit–cost analyses favored the interventions but only when costs were lower than market prices. The benefit–cost analysis results for hearing care services underscore their value when provided as part of a comprehensive rehabilitative plan that may inform future health policy changes.

100 Deals associated with Medioresinol

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ischemic stroke	Preclinical	China	China Pharmaceutical University	01 Jul 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Medioresinol

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation